|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||4.20 - 4.33|
|52 Week Range||2.67 - 7.39|
|PE Ratio (TTM)||100.00|
|Forward Dividend & Yield||0.00 (0.00%)|
|1y Target Est||4.00|
COLUMBIA, Md., Oct. 19, 2017-- Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present ...
COLUMBIA, Md., Oct. 05, 2017-- Osiris Therapeutics, Inc., a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced ...
NEW YORK, NY / ACCESSWIRE / March 29, 2017 / Stocks of both companies rose on future-oriented news for investors. While FDA clinical trials continue, both companies are getting positive news coverage from ...
Categories: Yahoo Finance Osiris Therapeutics, Inc. relative valuation is UNDERVALUED and it has a fundamental analysis score of 86. Our analysis is based on comparing Osiris Therapeutics, Inc. with the following peers – Vericel Corporation, Integra LifeSciences Holdings Corporation, Geron Corporation, Johnson & Johnson, Xtant Medical Holdings, Inc., CONMED Corporation, Nektar Therapeutics and Pluristem Therapeutics Inc. (VCEL-US, IART-US, ... Read more (Read more...)
NEW YORK, NY / ACCESSWIRE / March 14, 2017 / The competition between Osiris Therapeutics and competitor PTC has ended with an unceremonious thud. Osiris has come to the end of its NASDAQ run today, after ...
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]